According to the Zhītōng Cáijīng APP, Ayming Oncology-B (01541) showed abnormal rise during trading and increased nearly 3%. As of the closing, it increased by 0.71% to HKD 14.26.

It is worth noting that according to the company's WeChat public account message after market close, its wholly-owned subsidiary, Ayming Keer IMC-002 (CD47xCD20 mAb-Trap) project, has received approval from the National Medical Products Administration (NMPA) for the clinical study application (IND) of systemic lupus erythematosus (SLE).

Compared to CD20 monoclonal antibodies, the CD47xCD20 dual-targeting drug IMC-002 has a stronger clearance effect on peripheral blood B cells in SLE patients. In addition, literature has reported (J Pathol 2015; 237: 285–295) that knocking out CD47 in vivo can significantly reduce proteinuria levels in lupus nephritis model animals and significantly extend the lifespan of diseased animals. Therefore, the company believes that IMC-002 is expected to have good clinical efficacy for moderate to severe SLE.

Dr. Tian Wenzhi, founder and director of the company, said: "IMC-002 is a CD47xCD20 double-targeting antibody-receptor chimeric protein (mAb-Trap), and in vitro experiments have shown that it has a significantly stronger killing effect on B cells than rituximab. IMC-002 (1ug/ml) can significantly deplete CD19+ B cells in the peripheral blood of SLE patients, so we believe it will have a good therapeutic effect for B cell-related autoimmune diseases. We plan to conduct further exploratory studies in multiple indications and look forward to bringing good news to the vast number of autoimmune disease patients."